The ALCANZA phase III trial included patients with primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-expressing Mycosis Fungoides (MF) who had received one prior line of systemic therapy. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.